Is Community-Acquired Methicillin-Resistant Staphylococcus aureus Coverage Needed for Cellulitis?

Area of Science:

• Infectious Diseases
• Antimicrobial Therapy
• Dermatology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a prevalent pathogen in community-acquired skin and soft-tissue infections.
• Empirical treatment strategies often include MRSA coverage for various infections.
• The necessity of MRSA coverage for cellulitis remains a clinical question.

Purpose of the Study:

• To evaluate the need for empirical methicillin-resistant Staphylococcus aureus (MRSA) coverage in the treatment of cellulitis.
• To review the pathogenesis, microbiology, and current therapeutic studies for cellulitis.
• To determine appropriate antimicrobial therapy for community-acquired cellulitis.

Main Methods:

• Defined cellulitis and reviewed existing literature on its pathogenesis and microbiology.
• Analyzed current inpatient and outpatient antimicrobial therapy studies.
• Examined antibody studies to identify common etiologic agents.

Main Results:

• Evidence suggests empirical MRSA coverage is not essential for non-purulent (non-suppurative) cellulitis.
• Streptococci are identified as the most common etiologic agents in non-purulent cellulitis.
• Most non-purulent cellulitis cases are not suitable for microbiological culture.

Conclusions:

• Empirical MRSA coverage is likely unnecessary for non-purulent community-acquired cellulitis.
• Beta-lactam therapy, targeting streptococci, is generally sufficient for non-purulent cellulitis.
• Treatment decisions should consider the specific presentation and likely pathogens of cellulitis.